Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. MAPS Public Benefit Corporation will coordinate trial design with Medicines and Healthcare products Regulatory Agency to create a road map for early patient access in the UK. Corine de Boer, M.D.,

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

NewsMunchies

NOVEMBER 12, 2021

In clinical trials, psilocybin (the psychoactive substance in mushrooms) has shown tremendous promise in treating severe depression, post-traumatic stress disorder, and other mental illnesses. As such, magic mushroom therapy offers hope. Additional clinical trials underway in the U.S. In a typical year in the U.S.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

CannaMD

JUNE 2, 2021

Of those states that had legalized medical marijuana, 14 currently consider Parkinson’s disease a qualifying condition for medical marijuana therapies. More than 80% of survey respondents indicated strong interest in learning more information about a clinical trial, and more than half were interested in enrolling in a clinical trial.

Patients 105

Patients Clinical Trials Treatment Research and Development 105

Veriheal

MAY 26, 2022

In turn, cannabis advocates have struggled to properly educate the public with the limited amount of scientific evidence available. Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

TheAnswerPage

JANUARY 11, 2022

As the Editor-in-Chief of the medical education website called TheAnswerPage.com for nearly two decades, I have assessed multiple educational gaps in the healthcare community. Thus, an educational gap developed, creating a less than ideal situation for medical marijuana patients. So, why did this educational gap develop?

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 19, 2022

The Center for Psychedelic Drug Research and Education (CPDRE) was approved by the Ohio State College of Social Work faculty in January, and its director, Assistant Professor of Social Work Alan Davis , officially took the helm in March. Initial goals of the center are focused on research and educational initiatives. Jason Slot.

Education 52

Education Research and Development Therapy Clinical Trials 52

Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

JUNE 29, 2021

Synergetic Press and the Multidisciplinary Association for Psychedelic Science (MAPS) are pleased to announce they have entered into a copublishing relationship effective May 1, 2021 which will greatly expand the availability of education about psychedelics and psychedelic therapy. founder and executive director of MAPS.

Therapy 69

Therapy Research and Development Clinical Trials Education 69

Cannabis Life Network

SEPTEMBER 17, 2020

You’ve tried going to therapy, taking medications, receiving treatment at rehabilitation centres–everything. Imagine having a treatment-resistant addition. But none of it worked. Where do you even go from there? What else is there to do?

Therapy 113

Therapy Treatment Clinical Trials Education 113

Cannabis Law Report

JUNE 4, 2021

Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinical trial information: NCT03276572 ( [link] ). Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. PSA declines and CTC responses were clearly evident.

Data 100

Data Research and Development Clinical Trials Therapy 100

The Joint Blog

NOVEMBER 4, 2019

The study found that 58% of physicians agree that “medical cannabis was a legitimate medical therapy.” Many expressed a desire to receive additional education about cannabis in order to become better versed in the subject.” Over one-third of providers believed that medical cannabis interacted with medical therapies.

Therapy 42

Therapy Clinical Trials Conditions Patients 42

The Cannigma

AUGUST 31, 2021

Medical societies are slowly providing more CME (continuing medical education) to doctors on cannabis, however, that educational content tends to be slanted toward risk mitigation. Fortunately, there is a slowly growing community of cannabis physicians who are learning through trial and error and from one another.

Education 105

Education Clinical Trials Medicine Policy 105

Cannabis Law Report

JULY 27, 2021

plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment. Through research and education, Realm of Caring (RoC) is facilitating the mainstream acceptance of cannabinoid-based therapies and building an empowered community. About Realm of Caring.

Data 81

Data Epilepsy Research and Development Clinical Trials 81

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. MEDIA CONTACT .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

AUGUST 3, 2021

For CUNY, the Contract operationalizes the CDC’s ‘ Guidance for Institutions of Higher Education ’ aimed at disease control and minimizing the risk of exposure in education settings. FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S.

Clinical Trials 81

Clinical Trials Therapy Collective Research and Development 81

SpeedWeed

MAY 22, 2021

The US Food and Drug Administration (FDA) has just approved a new clinical trial that will allow therapists to legally use MDMA. For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. .

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

SpeedWeed

SEPTEMBER 17, 2021

million to assess the efficacy of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI). Wesana is a serious, thoughtful and ethical company engaged in the development of psychedelic-assisted therapy. Lately, MAPS research zeroed in on MDMA-assisted therapy for PTSD.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

MMJ Recs

JULY 11, 2024

Each type of insomnia may require different treatment approaches, including behavioral therapy, medication, lifestyle changes, or addressing underlying medical or psychological issues. However, more robust clinical trials are needed to validate these findings and determine the optimal dosages and treatment regimens for each disorder.

Sleep 111

Sleep Treatment Research and Development Therapy 111

Peninsula Alternative Health

MAY 15, 2019

Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. So far, science is telling us that yes cannabis has anti-seizure actions. References Staff, T.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

AUGUST 21, 2019

In November 2018, the legal status of cannabis was changed to allow specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need, following a high-profile media campaign. Doctors don’t have any education, training, and they don’t understand, she said.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. At 36, MAPS is now older than I was when I started MAPS at age 32.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

MAY 28, 2022

The firm represents clients around the world in major industries including energy and natural resources; financial services and capital markets; food and agribusiness; healthcare, life sciences and education; real estate, development and construction; and technology, manufacturing and transportation. How did this come to fruition?

Research and Development 52

Research and Development Therapy Clinical Trials Legalization 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression. The Project.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

DECEMBER 9, 2021

“We believe it is the responsibility of psychedelic-therapy companies to provide material support to the life-changing research being done in the space, which has made our work possible. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

SEPTEMBER 2, 2021

Suffolk County Community College joins new safeCircle client The City University of New York, as well as several existing higher education institution clients, who have turned to us for COVID-19 testing to support their 2021-2022 academic year,” stated Dr. James A. Hayward, president and CEO of Applied DNA. “As

Clinical Trials 76

Clinical Trials Research and Development Therapy Collective 76

LifeCannMD

MAY 27, 2025

” I completely understand this concern, and that’s exactly why I’m passionate about educating patients about microdosing cannabis. Just last week, I had a patient named Maria (not her real name) come into my LifeCannMD office.

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

Cannabis Law Report

DECEMBER 9, 2021

(the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“ N , N -Dimethyltryptamine or DMT”) at Canadian manufacturer Dalton Pharma Services.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 2, 2021

We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.” ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52

Cannabis Law Report

AUGUST 7, 2022

In recent years, as more clinical trial results show that psychedelics can be used in conjunction with therapy to treat illnesses like depression and post-traumatic stress disorder, legislators pushed to make certain substances available in certain settings. But these substances remain illegal under federal law.

Law 74

Law Research and Development Therapy Treatment 74

Puff Puff Post

DECEMBER 28, 2018

We go deep into what this might mean for the future of therapy for Autism Spectrum Disorders (ASD), and how we might see the use of CBD oil for autism. Success rates of up to 80% have been observed for CBD related autism therapy. Beyond alternative therapies, education and medication are the two most accepted ways of treating autism.

Treatment 76

Treatment Oil CBD Therapy 76

SpeedWeed

JULY 6, 2021

Last fall, Oregon became the first US state to legalize psilocybin-assisted therapy , and California legislators and activists are working to fully legalize psilocybin by the end of next year. The project also intends to advance research into how psychedelics can heal trauma and how to ensure equitable access to these therapies.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

JANUARY 27, 2022

Based on cohorts of children with special educational needs, the prevalence of fragile X syndrome (FXS) is estimated to be 1 in 4,000 in males, and 1 in 8,000 in females. The majority of industry-sponsored drugs in active clinical development for FXS are in Phase II, with two drugs in Phase III. CLINICAL TRIAL LANDSCAPE.

Clinical Trials 40

Clinical Trials Therapy Cannabinoids Topical 40

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

APRIL 21, 2022

MAPS PBC is pioneering new forms of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for post-traumatic stress disorder (PTSD). MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD.

Advocacy 52

Advocacy Therapy Clinical Trials Treatment 52

Cannabis Law Report

JUNE 25, 2021

EMA also regulates and supervises the drug quality, check for the intended use of the drug and whether the drug is meeting the requirement of clinical trial. Increasing use of biologics and targeted therapies is acting as a restraint in the skin cancer drugs market. The targeted therapies drugs targets melanoma cells only.

Research and Development 65

Research and Development Therapy Pharmaceutical Clinical Trials 65